Developer docs
API playgroundTry for free, no card

Search company profiles

Cytrellis Biosystems

Full company profile

uuid0000hu9

Namestring
Cytrellis Biosystems
Legal namestring
Cytrellis Biosystems, Inc.
Websiteurl
cytrellis.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Cytrellis Biosystems, Inc. is a private, venture-backed medical technology company headquartered in Woburn, Massachusetts, that develops and commercializes aesthetic devices. Its core product, the ellacor® System with Micro-Coring® Technology, is an FDA-cleared platform that uses proprietary hollow needles to mechanically extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The mechanism is positioned as the only nonsurgical treatment that physically removes excess skin without thermal energy or surgery; the November 2025 FDA clearance extends use to full-body resurfacing beyond the original mid and lower face indication. The company launched an upgraded ellacor 2.0 platform in January 2025 claiming a 35% reduction in treatment time and 60% faster healing relative to its predecessor.

The company monetizes through direct sale of the ellacor capital system to aesthetic medical practitioners (plastic surgeons, dermatologists, and aesthetic physicians) and through associated per-procedure consumables performed in-office. Go-to-market is enterprise field sales to individual practices, supported by physician training through a dedicated medical portal (aesthetics-central.com/info/cytrellis) and consumer-facing marketing via ellacor.com and brand social channels. As of early 2023 the company had delivered its 100th system and completed its 1,000th procedure; commercial scope has since expanded into Canada and Saudi Arabia following regulatory approvals in those jurisdictions, with the first Canadian launch at Lawrence Park Plastic Surgery in Toronto in March 2026.

Cytrellis is led by President and CEO Denise Dajles, PhD, with an operating team drawn from prior roles at Sientra, Merz Aesthetics, Allergan, and Establishment Labs, and a board chaired by John McDonough (former founding CEO of T2 Biosystems) and including Keith L. Crandell of ARCH Venture Partners as a director. Co-founders Rox Anderson, MD (Harvard/MIT, co-inventor of fractional laser treatment) and William Austen, Jr., MD (Chief of Plastic and Reconstructive Surgery at Mass General) anchor the clinical and scientific foundation. The technology is protected by at least eight issued U.S. patents covering the Micro-Coring method and device architecture.

Short descriptiontext

Cytrellis Biosystems is a private medical technology company that develops and commercializes the FDA-cleared ellacor system with proprietary Micro-Coring Technology for minimally invasive, nonsurgical skin removal, selling directly to plastic surgeons, dermatologists, and aesthetic physicians in the United States, Canada, and Saudi Arabia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical aesthetic devices, minimally invasive skin removal, micro-coring technology, dermatology medical devices, nonsurgical skin tightening
Industry1 code
PRIMARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Aesthetic Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Consumables Sales
TypeHardware Sales
Description

Cytrellis sells the ellacor system (hardware) and associated consumables to aesthetic medical practitioners. Procedures are performed in-office by trained physicians. Revenue is generated through device placement and per-procedure consumable usage.

cytrellis.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ellacor
Description

FDA-cleared Micro-Coring technology system for minimally invasive skin removal treatment of moderate to severe wrinkles in mid to lower face. Product line includes ellacor 2.0 with improved treatment time and healing.

cytrellis.com
+1 more record
Core offering1 text field

Cytrellis develops and commercializes the ellacor® System with Micro-Coring® Technology, an FDA-cleared minimally invasive medical device that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The system is the only nonsurgical treatment that removes excess skin without surgery or thermal injury and is indicated for moderate to severe wrinkles in the mid to lower face in adults 22+ with Fitzpatrick Skin Types I-IV. The company sells the device and associated consumables directly to aesthetic medical professionals for in-office use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 35% reduction in treatment time with ellacor 2.0
+3 more records
Product overview1 text field

Cytrellis Biosystems is a medical technology company dedicated to developing and commercializing first-in-class aesthetic devices. The company's primary product is the ellacor® System with Micro-Coring® Technology, an FDA-cleared system that removes sagging skin on the micro-scale using proprietary hollow needles. The core ellacor system treats moderate to severe wrinkles in the mid and lower face, while ellacor 2.0 represents a next-generation upgrade with improved treatment time and healing. The company operates ellacor.com as a patient-facing portal and an aesthetics-central medical portal for healthcare providers. Cytrellis holds multiple U.S. patents protecting the Micro-Coring Technology and has received regulatory approvals in the U.S., Canada, and Saudi Arabia.

Product and service2 records
1ellacor® System with Micro-Coring® Technology
CategoryAesthetic medical device (core product)
Description

FDA-cleared minimally invasive skin removal system that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. Indicated for treatment of moderate to severe wrinkles in the mid and lower face in adults aged 22+ with Fitzpatrick skin types I-IV, and used by aesthetic medical professionals (plastic surgeons, dermatologists) for in-office procedures.

2ellacor® 2.0
CategoryAesthetic medical device (product upgrade)
Description

Next-generation upgrade of the ellacor® System with Micro-Coring® Technology optimized for enhanced patient and provider experience, delivering 35% reduction in treatment time and 60% faster healing compared to the original system. Sold to aesthetic medical professionals for in-office use.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Lawrence Park Plastic Surgery
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-05
Description

Lawrence Park Plastic Surgery in Toronto is the first clinic in Canada to offer the ellacor system with Micro-Coring technology. Dr. Mathew Plant became the first plastic surgeon in Canada to perform the procedure. The launch marks Cytrellis' expansion into the Canadian market, positioning the technology as an alternative between non-invasive treatments and surgery for Canadian patients seeking skin restoration.

newswire.ca
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lumenis (acquired by Boston Scientific) manufactures the ResurFX and M22 platforms for fractional skin resurfacing, plus a broad surgical laser portfolio. Its aesthetic platforms compete with ellacor for skin rejuvenation procedure volumes in dermatology and plastic surgery practices.

2Candela Medical
TypeBroad incumbent
Description

Candela (acquired by Apax Partners) provides a broad portfolio of aesthetic energy-based devices (GentleLase, Vbeam, Nordlys, Profound) used by plastic surgeons and dermatologists. As a larger established player, it competes for the same practice capital and patient indications across multiple categories.

TypeDirect peer
Description

Cutera markets energy-based aesthetic devices (excel V+, truSculpt, Secret RF) to plastic surgeons and dermatologists for skin rejuvenation and body contouring. Its Secret RF microneedling platform and broader device portfolio compete for the same practice capital budget and patient indications as ellacor.

TypeDirect peer
Description

InMode develops minimally invasive and non-invasive aesthetic medical devices (BodyTite, Morpheus8, FaceTight) sold to plastic surgeons and dermatologists - the same physician channel Cytrellis targets. Its Morpheus8 microneedling RF platform directly competes with ellacor's skin remodeling proposition.

TypeDirect peer
Description

Cynosure is a leading developer of light-based and RF aesthetic systems (PicoSure, TempSure, Potenza) sold to medical aesthetic practices. Its Potenza microneedling RF device competes head-to-head with ellacor's skin remodeling value proposition.

6BTL Industries
TypeDirect peer
Description

BTL Industries makes Emface (non-invasive facial lifting), Emsculpt, and Exilis - all sold to aesthetic practices for skin and body treatment. Its Emface facial toning device competes with ellacor for the 'no-surgery facial rejuvenation' patient segment.

TypeDirect peer
Description

Venus Concept sells Venus Viva, Venus Versa, and other energy-based aesthetic devices used for skin resurfacing and tightening in medical aesthetic practices. Its Viva fractional RF system competes directly with ellacor for skin rejuvenation cases.

TypeDirect peer
Description

Solta Medical, a Bausch Health company, manufactures Thermage (RF skin tightening) and Fraxel (fractional laser), the legacy gold-standard skin rejuvenation devices in the same aesthetic practice channel as ellacor. Direct competitor for skin tightening and wrinkle reduction indications.

TypeEmerging player
Description

Apyx Medical markets the Renuvion system for subdermal skin tightening using helium plasma technology. Its minimally invasive skin contraction approach overlaps with ellacor's positioning between non-invasive treatments and surgery, targeting the same plastic surgeon channel.

TypeBroad incumbent
Description

AbbVie's Allergan Aesthetics division markets CoolSculpting and a portfolio of facial aesthetics products to plastic surgeons and dermatologists. As the largest aesthetics company globally, it sets competitive benchmarks and bundles offerings that compete for the same practice capital as ellacor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cytrellis Biosystems

Aesthetic Medical Devicescytrellis.com

Cytrellis Biosystems is a private medical technology company that develops and commercializes the FDA-cleared ellacor system with proprietary Micro-Coring Technology for minimally invasive, nonsurgical skin removal, selling directly to plastic surgeons, dermatologists, and aesthetic physicians in the United States, Canada, and Saudi Arabia.

What Cytrellis Biosystems does

Cytrellis Biosystems, Inc. is a private, venture-backed medical technology company headquartered in Woburn, Massachusetts, that develops and commercializes aesthetic devices. Its core product, the ellacor® System with Micro-Coring® Technology, is an FDA-cleared platform that uses proprietary hollow needles to mechanically extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The mechanism is positioned as the only nonsurgical treatment that physically removes excess skin without thermal energy or surgery; the November 2025 FDA clearance extends use to full-body resurfacing beyond the original mid and lower face indication. The company launched an upgraded ellacor 2.0 platform in January 2025 claiming a 35% reduction in treatment time and 60% faster healing relative to its predecessor.

The company monetizes through direct sale of the ellacor capital system to aesthetic medical practitioners (plastic surgeons, dermatologists, and aesthetic physicians) and through associated per-procedure consumables performed in-office. Go-to-market is enterprise field sales to individual practices, supported by physician training through a dedicated medical portal (aesthetics-central.com/info/cytrellis) and consumer-facing marketing via ellacor.com and brand social channels. As of early 2023 the company had delivered its 100th system and completed its 1,000th procedure; commercial scope has since expanded into Canada and Saudi Arabia following regulatory approvals in those jurisdictions, with the first Canadian launch at Lawrence Park Plastic Surgery in Toronto in March 2026.

Cytrellis is led by President and CEO Denise Dajles, PhD, with an operating team drawn from prior roles at Sientra, Merz Aesthetics, Allergan, and Establishment Labs, and a board chaired by John McDonough (former founding CEO of T2 Biosystems) and including Keith L. Crandell of ARCH Venture Partners as a director. Co-founders Rox Anderson, MD (Harvard/MIT, co-inventor of fractional laser treatment) and William Austen, Jr., MD (Chief of Plastic and Reconstructive Surgery at Mass General) anchor the clinical and scientific foundation. The technology is protected by at least eight issued U.S. patents covering the Micro-Coring method and device architecture.

Cytrellis Biosystems firmographics

Firmographics
Name
Cytrellis Biosystems
Legal name
Cytrellis Biosystems, Inc.
Website
https://cytrellis.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Cytrellis Biosystems is a private medical technology company that develops and commercializes the FDA-cleared ellacor system with proprietary Micro-Coring Technology for minimally invasive, nonsurgical skin removal, selling directly to plastic surgeons, dermatologists, and aesthetic physicians in the United States, Canada, and Saudi Arabia.
Ownership category
akta.pro rank

Cytrellis Biosystems industry classification

Industry
Product category
Aesthetic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYCRABAKAI
Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)

Keywords

  • Medical aesthetic devices
  • Minimally invasive skin removal
  • Micro-coring technology
  • Dermatology medical devices
  • Nonsurgical skin tightening

Where Cytrellis Biosystems is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cytrellis Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device and Consumables Sales: Cytrellis sells the ellacor system (hardware) and associated consumables to aesthetic medical practitioners. Procedures are performed in-office by trained physicians. Revenue is generated through device placement and per-procedure consumable usage.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Cytrellis Biosystems product offering

Product offering

Core offering

Cytrellis develops and commercializes the ellacor® System with Micro-Coring® Technology, an FDA-cleared minimally invasive medical device that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The system is the only nonsurgical treatment that removes excess skin without surgery or thermal injury and is indicated for moderate to severe wrinkles in the mid to lower face in adults 22+ with Fitzpatrick Skin Types I-IV. The company sells the device and associated consumables directly to aesthetic medical professionals for in-office use.

Product overview

Cytrellis Biosystems is a medical technology company dedicated to developing and commercializing first-in-class aesthetic devices. The company's primary product is the ellacor® System with Micro-Coring® Technology, an FDA-cleared system that removes sagging skin on the micro-scale using proprietary hollow needles. The core ellacor system treats moderate to severe wrinkles in the mid and lower face, while ellacor 2.0 represents a next-generation upgrade with improved treatment time and healing. The company operates ellacor.com as a patient-facing portal and an aesthetics-central medical portal for healthcare providers. Cytrellis holds multiple U.S. patents protecting the Micro-Coring Technology and has received regulatory approvals in the U.S., Canada, and Saudi Arabia.

Differentiator

Problem solved

Functional benefit

Brands

  • ellacor: FDA-cleared Micro-Coring technology system for minimally invasive skin removal treatment of moderate to severe wrinkles in mid to lower face. Product line includes ellacor 2.0 with improved treatment time and healing.
  • ellacor 2.0

Products and services

  • ellacor® System with Micro-Coring® Technology FDA-cleared minimally invasive skin removal system that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. Indicated for treatment of moderate to severe wrinkles in the mid and lower face in adults aged 22+ with Fitzpatrick skin types I-IV, and used by aesthetic medical professionals (plastic surgeons, dermatologists) for in-office procedures.
  • ellacor® 2.0 Next-generation upgrade of the ellacor® System with Micro-Coring® Technology optimized for enhanced patient and provider experience, delivering 35% reduction in treatment time and 60% faster healing compared to the original system. Sold to aesthetic medical professionals for in-office use.

Quantifiable outcome

  • 35% reduction in treatment time with ellacor 2.0
  • +3 more outcomes

Companies that use Cytrellis Biosystems

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Cytrellis Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cytrellis Biosystems partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lawrence Park Plastic SurgerycoreChannel Partner/ Reseller/ Distributor · 5 March 2026Lawrence Park Plastic Surgery in Toronto is the first clinic in Canada to offer the ellacor system with Micro-Coring technology. Dr. Mathew Plant became the first plastic surgeon in Canada to perform the procedure. The launch marks Cytrellis' expansion into the Canadian market, positioning the technology as an alternative between non-invasive treatments and surgery for Canadian patients seeking skin restoration.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Cytrellis Biosystems competitors and assessment

Company assessment

Broad incumbents

  • Lumenis (Boston Scientific): Lumenis (acquired by Boston Scientific) manufactures the ResurFX and M22 platforms for fractional skin resurfacing, plus a broad surgical laser portfolio. Its aesthetic platforms compete with ellacor for skin rejuvenation procedure volumes in dermatology and plastic surgery practices.
  • Candela Medical: Candela (acquired by Apax Partners) provides a broad portfolio of aesthetic energy-based devices (GentleLase, Vbeam, Nordlys, Profound) used by plastic surgeons and dermatologists. As a larger established player, it competes for the same practice capital and patient indications across multiple categories.
  • Allergan Aesthetics (AbbVie): AbbVie's Allergan Aesthetics division markets CoolSculpting and a portfolio of facial aesthetics products to plastic surgeons and dermatologists. As the largest aesthetics company globally, it sets competitive benchmarks and bundles offerings that compete for the same practice capital as ellacor.

Direct peers

  • Cutera, Inc. Cutera markets energy-based aesthetic devices (excel V+, truSculpt, Secret RF) to plastic surgeons and dermatologists for skin rejuvenation and body contouring. Its Secret RF microneedling platform and broader device portfolio compete for the same practice capital budget and patient indications as ellacor.
  • InMode Ltd. InMode develops minimally invasive and non-invasive aesthetic medical devices (BodyTite, Morpheus8, FaceTight) sold to plastic surgeons and dermatologists - the same physician channel Cytrellis targets. Its Morpheus8 microneedling RF platform directly competes with ellacor's skin remodeling proposition.
  • Cynosure (Hologic): Cynosure is a leading developer of light-based and RF aesthetic systems (PicoSure, TempSure, Potenza) sold to medical aesthetic practices. Its Potenza microneedling RF device competes head-to-head with ellacor's skin remodeling value proposition.
  • BTL Industries: BTL Industries makes Emface (non-invasive facial lifting), Emsculpt, and Exilis - all sold to aesthetic practices for skin and body treatment. Its Emface facial toning device competes with ellacor for the 'no-surgery facial rejuvenation' patient segment.
  • Venus Concept: Venus Concept sells Venus Viva, Venus Versa, and other energy-based aesthetic devices used for skin resurfacing and tightening in medical aesthetic practices. Its Viva fractional RF system competes directly with ellacor for skin rejuvenation cases.
  • Solta Medical (Bausch Health): Solta Medical, a Bausch Health company, manufactures Thermage (RF skin tightening) and Fraxel (fractional laser), the legacy gold-standard skin rejuvenation devices in the same aesthetic practice channel as ellacor. Direct competitor for skin tightening and wrinkle reduction indications.

Emerging players

  • Apyx Medical (Renuvion): Apyx Medical markets the Renuvion system for subdermal skin tightening using helium plasma technology. Its minimally invasive skin contraction approach overlaps with ellacor's positioning between non-invasive treatments and surgery, targeting the same plastic surgeon channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cytrellis Biosystems social profiles

Digital presence

Cytrellis Biosystems compliance and trust

Trust signal

Compliance1 record

Cytrellis Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cytrellis Biosystems leadership team

Management profile

Number of profiles

Profiles14 records

Cytrellis Biosystems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cytrellis Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytrellis Biosystems

What does Cytrellis Biosystems do?

Cytrellis develops and commercializes the ellacor® System with Micro-Coring® Technology, an FDA-cleared minimally invasive medical device that uses proprietary hollow needles to extract micro-cores of dermal and epidermal tissue while stimulating natural collagen and elastin production. The system is the only nonsurgical treatment that removes excess skin without surgery or thermal injury and is indicated for moderate to severe wrinkles in the mid to lower face in adults 22+ with Fitzpatrick Skin Types I-IV. The company sells the device and associated consumables directly to aesthetic medical professionals for in-office use.

Is Cytrellis Biosystems a public or private company?

Cytrellis Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cytrellis Biosystems founded?

Cytrellis Biosystems was founded in 2016. It employs 51 to 100 people.

Where is Cytrellis Biosystems based?

Cytrellis Biosystems is headquartered in Woburn, United States, in the North America region.

How does Cytrellis Biosystems make money?

One revenue line is on record: medical Device and Consumables Sales.

Who are Cytrellis Biosystems's main competitors?

Broad incumbents on record are Lumenis (Boston Scientific), Candela Medical and Allergan Aesthetics (AbbVie). Direct peers are Cutera, Inc., InMode Ltd., Cynosure (Hologic), BTL Industries, Venus Concept and Solta Medical (Bausch Health). Apyx Medical (Renuvion) is listed as an emerging player.

Does Cytrellis Biosystems have an API?

No public API is recorded for Cytrellis Biosystems.

What industry is Cytrellis Biosystems in?

Cytrellis Biosystems's product category is Aesthetic Medical Devices. Its primary akta.pro industry code is CRABAKAI, Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCytrellis Launches ellacor® Micro-Coring® Technology for Full-Body Skin Resurfacing in AustraliaCytrellis launched ellacor with Micro-Coring Technology in Australia after Therapeutic Goods Administration approval. The device removes micro-cores of skin for full-body resurfacing, including neck, abdomen, arms, thighs, and knees, without surgery or thermal injury. The company plans to expand internationally.Dermatology TimesMicro-Coring Revolutionized: Cytrellis' Denise Dajles, DEng, MSc, on Evolving Skin Treatments with Ellacor 2.0Cytrellis Biosystems has launched the ellacor 2.0 system, an updated version of its FDA-cleared micro-coring device for minimally invasive skin removal. The new iteration features improved needle design and software that reduce procedure time by approximately 35% and downtime by 60%, following a recent financing round. This release builds on the original technology's clinical efficacy in treating moderate to severe wrinkles without scarring.EntrepreneurThe Woman Rewriting the Rules of Aesthetics: Inside Denise Dajles’ Bold Bet With CytrellisDenise Dajles, CEO of Cytrellis Biosystems, is leading the company's commercialization of ellacor, a first-in-class skin removal device using Micro-Coring Technology that offers an alternative to surgery for patients with skin laxity. The company is targeting a growing market gap driven by aging populations and GLP-1 weight loss medications, which are leaving millions of patients with excess skin on the face and body. Cytrellis currently operates in six international markets including Canada, Saudi Arabia, UAE, South Africa, Japan, and South Korea, and has accumulated over 10 clinical studies and peer-reviewed publications to support its technology.NewswireCytrellis Expands into Canada with ellacor® Launch at Lawrence Park Plastic SurgeryCytrellis Biosystems announced the launch of its ellacor® system with Micro-Coring™ Technology at Lawrence Park Plastic Surgery in Toronto, marking the company's expansion into the Canadian market. Dr. Mathew Plant became the first plastic surgeon in Canada to offer this FDA-cleared, minimally invasive skin removal procedure, which removes excess skin through precise micro-scale coring without traditional surgery. The launch positions the technology as an alternative between non-invasive treatments and surgery for Canadian patients seeking skin restoration.GlobeNewswireNon-Surgical Skin Tightening Market to Reach US$ 3.8 Billion by 2033 | Astute AnalyticaAccording to market research from Astute Analytica, the global non-surgical skin tightening market was valued at US$ 1.9 billion in 2024 and is projected to reach US$ 3.8 billion by 2033, growing at a compound annual growth rate of 7.6%. Regulatory approvals are accelerating market expansion, with Venus Concept securing FDA 510(k) clearance for its Venus NOVA platform in November 2025 and Cytrellis receiving expanded FDA clearance for its Ellacor micro-coring device for use on arms, knees, and abdomen. Industry players including Solta Medical (launching Thermage in Canada), Merz Aesthetics (launching Ultherapy PRIME), and InMode (expanding BodyTite) are investing heavily in next-generation technology to capture growing demand driven by consumer preference for minimally invasive procedures.ThedermdigestU.S. FDA Clears Ellacor Micro-coring Technology for Full Body ResurfacingThe U.S. FDA cleared Cytrellis Biosystems' ellacor micro-coring device for treating sagging skin on body areas, expanding its use beyond the face. The device removes micro-cores of skin without surgery or heat, stimulating collagen and elastin production. Cytrellis executives highlighted the technology's precision and lack of scarring.ThedermdigestMeet ellacor 2.0Cytrellis Biosystems is launching ellacor 2.0, an updated version of its FDA-cleared Micro-Coring system designed to remove sagging skin and treat wrinkles. The new iteration features enhanced needle design and software that doubles treatment velocity while increasing suction strength by 30%. Clinical testing with over 100 patients demonstrated reduced downtime and improved patient comfort compared to the previous generation.Dermatology TimesDenise Dajles, DEng, MSc, Ushers in a New Era at Cytrellis Biosystems, Looks to Future of Aesthetics IndustryDenise Dajles has been appointed as the new president and CEO of Cytrellis Biosystems, Inc., aiming to expand the company's impact in the aesthetics industry. She plans to leverage the firm's proprietary Micro-Coring technology, specifically the ellacor system, to address emerging market demands such as sagging skin associated with GLP-1 weight loss treatments.MedspaproeventGame-Changing Advances: The Latest Innovations Shaping the Medical Aesthetics IndustryCytrellis Biosystems unveiled ellacor® 2.0, an upgraded minimally invasive skin removal system featuring a 35% reduction in treatment time and 60% faster healing compared to its predecessor. Galderma announced positive interim results for its injectable aesthetics portfolio addressing facial volume loss in GLP-1 medication patients, along with Phase IIIb trial data showing RelabotulinumtoxinA (Relfydess™) achieved rapid onset and sustained results through six months. Evolus received FDA approval for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid gels for nasolabial folds, with U.S. market launch planned for Q2 2025.